{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:05:30Z","timestamp":1793325930660,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05529-5","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T08:03:58Z","timestamp":1722845038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Identification and validation of inflammatory subtypes in intrahepatic cholangiocellular carcinoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Biao","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"issue":"6","key":"5529_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol. 2014;60(6):1268\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2014.01.021.","journal-title":"J Hepatol"},{"issue":"47","key":"5529_CR2","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.3748\/wjg.15.5976","volume":"15","author":"WF Shen","year":"2009","unstructured":"Shen WF, Zhong W, Xu F, et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma[J]. World J Gastroenterol. 2009;15(47):5976\u201382. https:\/\/doi.org\/10.3748\/wjg.15.5976.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"5529_CR3","doi-asserted-by":"publisher","first-page":"1145164509","DOI":"10.1177\/1073274817729245","volume":"24","author":"NN Massarweh","year":"2017","unstructured":"Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Control. 2017;24(3):1145164509. https:\/\/doi.org\/10.1177\/1073274817729245.","journal-title":"Cancer Control"},{"issue":"7225","key":"5529_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/457036b","volume":"457","author":"A Mantovani","year":"2009","unstructured":"Mantovani A, Cancer. Inflaming metastasis[J]. Nature. 2009;457(7225):36\u20137. https:\/\/doi.org\/10.1038\/457036b.","journal-title":"Nature"},{"key":"5529_CR5","doi-asserted-by":"publisher","unstructured":"Landskron G, De la Fuente M, Thuwajit P et al. Chronic inflammation and cytokines in the tumor microenvironment[J]. J Immunol Res, 2014,2014:149185. https:\/\/doi.org\/10.1155\/2014\/149185","DOI":"10.1155\/2014\/149185"},{"issue":"1","key":"5529_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention[J]. Signal Transduct Target Ther. 2021;6(1):263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"5529_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth[J]. Cancer Cell. 2023;41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016.","journal-title":"Cancer Cell"},{"issue":"1","key":"5529_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","volume":"52","author":"J Galon","year":"2020","unstructured":"Galon J, Bruni D. Tumor Immunology and Tumor Evolution: intertwined Histories[J]. Immunity. 2020;52(1):55\u201381. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.018.","journal-title":"Immunity"},{"issue":"12","key":"5529_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan NV, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers[J]. Exp Mol Med. 2018;50(12):1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0191-1.","journal-title":"Exp Mol Med"},{"key":"5529_CR10","doi-asserted-by":"publisher","first-page":"669587","DOI":"10.3389\/fmed.2021.669587","volume":"8","author":"KR Shieh","year":"2021","unstructured":"Shieh KR, Huang A, Xu Y. Response to Immune checkpoint inhibitor treatment in Advanced Cervical Cancer and Biomarker Study[J]. Front Med (Lausanne). 2021;8:669587. https:\/\/doi.org\/10.3389\/fmed.2021.669587.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"5529_CR11","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with Cancer who are eligible for and respond to checkpoint inhibitor immunotherapy Drugs[J]. JAMA Netw Open. 2019;2(5):e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"5529_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41571-020-00459-9","volume":"18","author":"J Hou","year":"2021","unstructured":"Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?[J]. Nat Rev Clin Oncol. 2021;18(5):261\u201379. https:\/\/doi.org\/10.1038\/s41571-020-00459-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"5529_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","volume":"40","author":"L Dong","year":"2022","unstructured":"Dong L, Lu D, Chen R, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma[J]. Cancer Cell. 2022;40(1):70\u201387. https:\/\/doi.org\/10.1016\/j.ccell.2021.12.006.","journal-title":"Cancer Cell"},{"issue":"51","key":"5529_CR14","doi-asserted-by":"publisher","first-page":"g3750","DOI":"10.1126\/sciadv.abg3750","volume":"7","author":"R Wu","year":"2021","unstructured":"Wu R, Guo W, Qiu X, et al. Comprehensive analysis of spatial architecture in primary liver cancer[J]. Sci Adv. 2021;7(51):g3750. https:\/\/doi.org\/10.1126\/sciadv.abg3750.","journal-title":"Sci Adv"},{"issue":"3","key":"5529_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/jso.21488","volume":"101","author":"L Zhang","year":"2010","unstructured":"Zhang L, Cai JQ, Zhao JJ, et al. Impact of hepatitis B virus infection on outcome following resection for intrahepatic cholangiocarcinoma[J]. J Surg Oncol. 2010;101(3):233\u20138. https:\/\/doi.org\/10.1002\/jso.21488.","journal-title":"J Surg Oncol"},{"issue":"1","key":"5529_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1681\/ASN.2017050544","volume":"29","author":"W Wu","year":"2018","unstructured":"Wu W, Liu C, Farrar CA, et al. Collectin-11 promotes the development of renal Tubulointerstitial Fibrosis[J]. J Am Soc Nephrol. 2018;29(1):168\u201381. https:\/\/doi.org\/10.1681\/ASN.2017050544.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"5529_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer[J]. Nat Rev Immunol. 2018;18(12):773\u201389. https:\/\/doi.org\/10.1038\/s41577-018-0066-7.","journal-title":"Nat Rev Immunol"},{"key":"5529_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.11.009","author":"K Boelaars","year":"2023","unstructured":"Boelaars K, van Kooyk Y. Targeting myeloid cells for cancer immunotherapy: Siglec-7\/9\/10\/15 and their ligands[J]. Trends Cancer. 2023. https:\/\/doi.org\/10.1016\/j.trecan.2023.11.009.","journal-title":"Trends Cancer"},{"issue":"8","key":"5529_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/art.41696","volume":"73","author":"N Wang","year":"2021","unstructured":"Wang N, Wu W, Qiang C, et al. Protective role of Collectin 11 in a mouse model of rheumatoid Arthritis[J]. Arthritis Rheumatol. 2021;73(8):1430\u201340. https:\/\/doi.org\/10.1002\/art.41696.","journal-title":"Arthritis Rheumatol"},{"key":"5529_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.11.031","author":"KY Wu","year":"2023","unstructured":"Wu KY, Cao B, Chen WB, et al. Collectin 11 has a pivotal role in host defense against kidney and bladder infection in mice[J]. Kidney Int. 2023. https:\/\/doi.org\/10.1016\/j.kint.2023.11.031.","journal-title":"Kidney Int"},{"issue":"8","key":"5529_CR21","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions[J]. Cell. 2023;186(8):1652\u201369. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006.","journal-title":"Cell"},{"issue":"10","key":"5529_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2023.3295","volume":"9","author":"AV Serritella","year":"2023","unstructured":"Serritella AV, Shenoy NK. Nivolumab Plus Ipilimumab vs Nivolumab alone in Advanced Cancers Other Than Melanoma: a Meta-Analysis[J]. JAMA Oncol. 2023;9(10):1441\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3295.","journal-title":"JAMA Oncol"},{"issue":"10088","key":"5529_CR23","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial[J]. Lancet. 2017;389(10088):2492\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2.","journal-title":"Lancet"},{"issue":"15","key":"5529_CR24","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab with Tumor Response and Survival among patients with Advanced Melanoma[J]. JAMA. 2016;315(15):1600\u20139. https:\/\/doi.org\/10.1001\/jama.2016.4059.","journal-title":"JAMA"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05529-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T08:07:02Z","timestamp":1722845222000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05529-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5529"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05529-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4090581\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from each patient for the use of patient samples, and the study was approved by the First Medical Center of the General Hospital of the Chinese People\u2019s Liberation Army (S2018-111-01). The study was performed in accordance with the recommendations of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"730"}}